Ghent University Hospital
Ghent, 9000, Belgium
NCT Number: NCT01911533
Hypothesis:
Extracorporeal removal of CO2 can treat hypercapnia and respiratory acidosis, which allows application of lung protective ventilation. This downgrading of mechanical ventilation promotes better and more quickly lung recovery.
Aim:
The aim of the study is to treat respiratory acidosis and to reduce plateau pressures by using an extracorporeal removal of CO2 (ECCO2-R).
This prospective study will include 10 patients with an Acute Respiratory Distress Syndrome (ARDS). ARDS is an inflammatory response in the lungs, the onset is acute with pulmonary oedema and shows bilateral densities on chest radiography. The take up of oxygen and the loss of CO2 in the lungs are difficult. Moreover the patient's blood can become acidic due to too much CO2.
To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
The investigators will use a standard dialysis catheter that will be put in a large vein. To prevent clotting of the system, the patient will receive heparin.
In the study the investigators will work in periods of two hours, the situation before and after carbon dioxide removal will be compared. With this study the investigators want to prove that the CO2 in the blood decreases with at least 20 % with the use of the extracorporeal CO2 remover. More over the investigators want to prove that lower mechanical ventilation settings (thanks to CO2-removal by the ECCO2-R) will produce fewer lesions to the lungs.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Ghent, 9000, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
Patients are their own control group.
Time frame: After the first two hours of ECCO2-R therapy, every 2 hours for a maximum of 5 days.
Arterial blood gasses, ventilator settings will be measured.
Time frame: Every 2 hours during procedure for a maximum of 5 days.
Arterial blood gasses and ventilator settings will be measured.
Time frame: Every 2 hours during the procedure for a maximum of 5 days.
Arterial blood gasses and ventilator settings will be measured.
Time frame: Every 2 hours during the procedure for a maximum of 5 days.
Arterial blood gasses and ventilator settings will be measured.
University Hospital, Ghent
Other
Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05825534
Acute Lung Injury, Acute Respiratory Distress Syndrome
Amiens, France
View Trial DetailsNCT05930418
Acute Respiratory Distress Syndrome, Cardiovascular Diseases
Memphis, Tennessee, United States
View Trial DetailsNCT03799874
Acute Respiratory Distress Syndrome, Lung Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05894291
Acute Respiratory Distress Syndrome, Lung Diseases
Orléans, France
View Trial Details